اطلاعات داروی نمایش داده شده مستقیما از دیتابیس اطلاعات دارویی سازمان غذا و دارو آمریکا (FDA)  استخراج می شود و مرتبا به روز رسانی می شود
داروی نمایش داده شده مورد تایید FDA  می باشد و اطلاعات ثبت آن در زیر قابل مشاهده است
AGENERASE از شرکت GLAXOSMITHKLINE
   New Drug Application (NDA): 021007
    
Company: GLAXOSMITHKLINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS | 
|---|---|---|---|---|---|---|---|
| AGENERASE | AMPRENAVIR | 50MG | CAPSULE;ORAL | Discontinued | 
 None  | 
No | No | 
| AGENERASE | AMPRENAVIR | 150MG | CAPSULE;ORAL | Discontinued | 
 None  | 
No | No | 
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url | 
|---|---|---|---|---|---|---|---|
| 04/15/1999 | ORIG-1 | Approval | 
 Type 1 – New Molecular Entity  | 
 
  | 
         https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf  | 
Supplements
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url | 
|---|---|---|---|---|---|
| 11/04/2005 | SUPPL-17 | Labeling | 
 https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021007s017ltr.pdf  | 
||
| 02/12/2004 | SUPPL-16 | Labeling | 
 https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21007slr016,21039slr016_agenerase_lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21007slr016,21039slr016ltr.pdf  | 
||
| 10/02/2002 | SUPPL-15 | Labeling | 
 https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21007s14s15,21039s13s14lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21007slr014,015,21039slr013,014ltr.pdf  | 
||
| 10/02/2002 | SUPPL-14 | Labeling | 
 https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21007s14s15,21039s13s14lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21007slr014,015,21039slr013,014ltr.pdf  | 
||
| 02/05/2002 | SUPPL-13 | Labeling | 
 Label is not available on this site.  | 
 https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21039s9s12ltr.pdf  | 
|
| 08/02/2002 | SUPPL-11 | Labeling | 
 https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21007s11,21039s10lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21007slr011and21039slr010ltr.pdf  | 
||
| 02/05/2002 | SUPPL-10 | Efficacy-Labeling Change With Clinical Data | 
 Label is not available on this site.  | 
 https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21039s9s12ltr.pdf  | 
|
| 05/09/2001 | SUPPL-9 | Labeling | 
 Label is not available on this site.  | 
||
| 12/14/2000 | SUPPL-8 | Manufacturing (CMC) | 
 Label is not available on this site.  | 
||
| 05/11/2001 | SUPPL-6 | 
 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/N21-007SE7006_Agenerase_Prntlbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/N21-007SE7006_Agenerase_Approv.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/N21-007S006_Agenerase.cfm  | 
|||
| 12/19/2000 | SUPPL-5 | Labeling | 
 Label is not available on this site.  | 
||
| 12/22/1999 | SUPPL-4 | Manufacturing (CMC) | 
 Label is not available on this site.  | 
||
| 04/24/2000 | SUPPL-3 | Labeling | 
 Label is not available on this site.  | 
||
| 04/28/2000 | SUPPL-2 | Labeling | 
 Label is not available on this site.  | 
||
| 09/22/1999 | SUPPL-1 | Labeling | 
 Label is not available on this site.  | 
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert  | 
Note | Url | 
|---|---|---|---|---|---|
| 11/04/2005 | SUPPL-17 | 
 Labeling  | 
Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf | |
| 02/12/2004 | SUPPL-16 | 
 Labeling  | 
Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21007slr016,21039slr016_agenerase_lbl.pdf | |
| 10/02/2002 | SUPPL-15 | 
 Labeling  | 
Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21007s14s15,21039s13s14lbl.pdf | |
| 10/02/2002 | SUPPL-14 | 
 Labeling  | 
Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21007s14s15,21039s13s14lbl.pdf | |
| 08/02/2002 | SUPPL-11 | 
 Labeling  | 
Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21007s11,21039s10lbl.pdf | |
| 05/11/2001 | SUPPL-6 | 
 Efficacy  | 
Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/N21-007SE7006_Agenerase_Prntlbl.pdf | |
| 04/15/1999 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf | 
                
                  
                                                
                                                
                                                
                                                
                                                
                                                
                                                
                                                
                                                
                                                
                                                
                                                
                                                
                                                
                                                
نظرات کاربران